All things considered, it has been concluded that the combination of DUSP2 methylation with EGFR expression levels and TP53 mutation status may represent a biomarker for the prediction of response to CRT in LA-HNSCC [82]. Here, DUSP2 is linked to head and neck squamous cell carcinoma.